EU Approves Enhertu Combo for First-Line HER2+ Breast Cancer
The European Commission approved Enhertu with pertuzumab as first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer.
This article was automatically drafted and passed editorial compliance checks. It synthesizes public source metadata and is not a substitute for individual care or clinical review.
AstraZeneca and Daiichi Sankyo announced on September 1 that the European Union had authorized Enhertu, or trastuzumab deruxtecan, with pertuzumab for first-line treatment of adults whose unresectable or metastatic breast cancer is HER2-positive by IHC 3+ or ISH+.
The authorization places the combination at the start of treatment rather than after another regimen. It concerns a defined HER2-positive population and does not mean that Enhertu has become first-line treatment for every breast cancer subtype.
What the EU authorization changes
The European Commission authorized the pairing of a HER2-directed antibody-drug conjugate with pertuzumab for first-line use in eligible adults. AstraZeneca and Daiichi Sankyo described it as the first newly authorized first-line regimen for HER2-positive metastatic breast cancer in Europe in more than a decade.
Eligibility depends on both disease setting and biomarker status: the cancer must be unresectable or metastatic and HER2-positive by IHC 3+ or ISH+. A qualified oncology team should confirm how the authorization relates to a patient's diagnosis and prior treatment.
Limits and treatment context
The August 24 coverage addressed how Enhertu was changing strategy in hormone receptor-positive breast cancer after progression on first-line endocrine therapy plus a CDK4/6 inhibitor. That article did not establish the separate EU authorization described in the September 2 report, so the regulatory event should not be extended to hormone receptor-positive disease generally.
The summaries do not quantify effectiveness, side effects, or recovery considerations for the newly authorized combination. These factors can involve individual variation, so patients should consult a qualified oncologist about anticipated benefits, monitoring, and treatment burden.
Questions for an oncology consultation
Patients can ask whether their pathology record documents IHC 3+ or ISH+ HER2-positive disease and whether the cancer meets the unresectable or metastatic criterion. They can also ask how hormone receptor status and previous therapy affect the treatment plan.
Before deciding, patients should ask what side effects require monitoring, how treatment may affect daily life and recovery between visits, and what alternatives apply to their circumstances. The oncology team can explain these points according to the patient's health, cancer characteristics, and individual variation.
Frequently asked questions
Who qualifies for the newly authorized Enhertu combination?
The European Commission authorized Enhertu with pertuzumab for adults with unresectable or metastatic HER2-positive breast cancer defined as IHC 3+ or ISH+. A qualified oncology team must determine whether an individual patient meets those criteria.
Is the combination now a first-line treatment in the EU?
Yes, the authorization covers first-line treatment for the specified adult HER2-positive population. AstraZeneca and Daiichi Sankyo announced the EU decision on September 1.
Does this EU decision apply to all hormone-positive breast cancer?
No such broad application is established here. The EU authorization is defined by unresectable or metastatic disease and HER2 positivity by IHC 3+ or ISH+, while the August 24 article discussed a different treatment-strategy context in hormone receptor-positive disease.
Questions to take to your oncology appointment
- Does my pathology show HER2 positivity by IHC 3+ or ISH+?
- Does my disease meet the unresectable or metastatic criteria in the EU authorization?
- How do my hormone receptor status and previous treatments affect eligibility?
- Which side effects would require monitoring during combination treatment?
- What should I expect regarding daily activities and recovery between treatments?
MediIndex articles are for general information only and are not medical advice, diagnosis, or advertising. Outcomes vary by individual — consult a board-certified specialist for personal decisions.
